Milner John, McNeil Brian, Alioto Joe, Proud Kevin, Rubinas Tara, Picken Maria, Demos Terrence, Turk Thomas, Perry Kent T
Loyola University, Chicago, Illinois, USA.
J Urol. 2006 Sep;176(3):905-9. doi: 10.1016/j.juro.2006.04.016.
We reviewed our experience with fat poor cases of angiomyolipoma.
The records of patients with angiomyolipoma, as determined by pathological study, from 1998 to 2004 were reviewed by recording patient demographics and outcomes. Fat poor cases were defined as the failure of imaging to demonstrate fat in a lesion. Computerized tomography and histological characteristics were assessed.
Histologically confirmed angiomyolipoma was found in 15 patients. Multiple lesions were found in 3 of 15 cases (20%). Of these 15 patients who underwent surgery 11 (73%) had unsuspected angiomyolipoma due to absent fat on computerized tomography and they underwent intervention for presumed renal cell carcinoma. Mean age +/- SD in this group was 54 +/- 15 years and 8 of 11 patients (73%) were female, of whom 4 (50%) had uterine fibroids. These lesions were found incidentally in 7 of 11 cases (64%). Operative complications developed in 2 of 11 patients (18%). Average maximal diameter on pathological evaluation was 3.2 +/- 1.3 cm (range 1.5 to 6). Nonenhanced computerized tomography was available in 7 of 11 cases, of which 3 of 7 (42%) showed hyperdense lesions and 4 of 7 (57%) showed isodense lesions. The percent of fat identified per high power field was less than 25% in 12 of 13 fat poor angiomyolipoma lesions (92%) compared to 2 of 4 classic lesions (50%) known to be angiomyolipoma before surgery (p = 0.04).
We suggest that a general definition of fat poor angiomyolipoma should be the failure of imaging to reveal fat within a lesion, thus, making it unsuspected at surgery. A pathological definition should be less than 25% fat per high power field, which to our knowledge is a formerly undefined quantity. Not all cases are hyperdense on nonenhanced computerized tomography. These lesions cannot be reliably identified by imaging and they should be managed like all enhancing renal masses.
我们回顾了我们在脂肪含量少的肾血管平滑肌脂肪瘤病例方面的经验。
回顾了1998年至2004年经病理研究确诊为肾血管平滑肌脂肪瘤患者的记录,记录患者的人口统计学资料和治疗结果。脂肪含量少的病例定义为影像学检查未能在病变中显示脂肪。评估了计算机断层扫描和组织学特征。
15例患者经组织学证实为肾血管平滑肌脂肪瘤。15例中有3例(20%)发现有多个病灶。在这15例接受手术的患者中,11例(73%)因计算机断层扫描未显示脂肪而未被怀疑患有肾血管平滑肌脂肪瘤,他们因疑似肾细胞癌而接受了干预治疗。该组患者的平均年龄±标准差为54±15岁,11例患者中有8例(73%)为女性,其中4例(50%)患有子宫肌瘤。11例中有7例(64%)是偶然发现这些病灶的。11例患者中有2例(18%)出现手术并发症。病理评估时的平均最大直径为3.2±1.3厘米(范围为1.5至6厘米)。11例中有7例可获得非增强计算机断层扫描结果,其中7例中有3例(42%)显示为高密度病灶,7例中有4例(57%)显示为等密度病灶。与术前已知为肾血管平滑肌脂肪瘤的4例典型病灶中的2例(50%)相比,13例脂肪含量少的肾血管平滑肌脂肪瘤病灶中有12例(92%)在高倍视野下识别出的脂肪百分比低于25%(p = 0.04)。
我们建议,脂肪含量少的肾血管平滑肌脂肪瘤的一般定义应为影像学检查未能在病变中发现脂肪,因此在手术时未被怀疑。病理定义应为高倍视野下脂肪含量低于25%,据我们所知,这是一个以前未定义的量。并非所有病例在非增强计算机断层扫描上都是高密度的。这些病灶不能通过影像学可靠地识别,应像所有强化的肾肿块一样进行处理。